Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies

Journal of Substance Abuse Treatment

Volumn 47, Issue 2, 2014, Pages 113-121

  Hartung, Daniel M ^a   McCarty, Dennis ^b   Fu, Rongwei ^b   Wiest, Katharina ^c   Chalk, Mady ^d   Gastfriend, David R ^e  

^a OREGON STATE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c CODA ^*  (United States)

^d TREATMENT RESEARCH INSTITUTE   (United States)

^e ALKERMES INC   (United States)

Author keywords

Alcohol dependence; Naltrexone; Opioid dependence

Indexed keywords

DELAYED RELEASE FORMULATION; NALTREXONE; NARCOTIC ANTAGONIST;

ALCOHOLISM; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; ECONOMICS; HEALTH CARE COST; HUMAN; MEDICATION COMPLIANCE; META ANALYSIS; OPIOID-RELATED DISORDERS;

ALCOHOLISM; DELAYED-ACTION PREPARATIONS; HEALTH CARE COSTS; HUMANS; MEDICATION ADHERENCE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS;

EID: 84903177521     PISSN: 07405472     EISSN: 18736483     Source Type: Journal    
DOI: 10.1016/j.jsat.2014.03.007     Document Type: Article

References (40)

1. Agency for Healthcare Research and Quality. Methods guide for effectiveness and compartive effectiveness reviews publication no. 10(12)-EHC063-EF 2012, (Rockville, MD: Retreived from www.effectivehealthcare.ahrq.gov).
2. Bailey J.E., Hajjar M., Shoib B., Tang J., Ray M.M., Wan J.Y. Risk factors associated with antihypertensive medication nonadherence in a statewide medicaid population. The American Journal of the Medical Sciences 2012, 1-6. 10.1097/MAJ.0b013e31825ce50f.
3. Baser O., Chalk M., Fiellin D.A., Gastfriend D.R. Cost and utilization outcomes of opioid-dependence treatments. The American Journal of Managed Care 2011, 17(Suppl 8):S235-S248.
4. Baser O., Chalk M., Rawson R., Gastfriend D.R. Alcohol dependence treatments: Comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence. The American Journal of Managed Care 2011, 17(Suppl 8):S222-S234.
5. Berg K.M., Kunins H.V., Jackson J.L., Nahvi S., Chaudhry A., Harris K.A., et al. Association between alcohol consumption and both osteoporotic fracture and bone density. The American Journal of Medicine 2008, 121:406-418. 10.1016/j.amjmed.2007.12.012.
6. Boswell K.A., Cook C.L., Burch S.P., Eaddy M.T., Cantrell C.R. Associating medication adherence with improved outcomes: A systematic literature review. American Journal of Pharmacy Benefits 2012, 4:e97-e108.
7. Bryson W.C., McConnell J., Korthuis P.T., McCarty D. Extended-release naltrexone for alcohol dependence: Persistence and healthcare costs and utilization. The American Journal of Managed Care 2011, 17(Suppl 8):S222-S234.
8. Cohen J. Statistical power analysis for the behavioral sciences 1988, L. Erlbaum Associates, Hillsdale, NJ.
9. Cornish R., Macleod J., Strang J., Vickerman P., Hickman M. Risk of death during and after opiate substitution treatment in primary care: Prospective observational study in UK General Practice Research Database. BMJ 2010, 341:c5475. 10.1136/bmj.c5475.
10. Gastfriend D.R. Intramuscular extended-release naltrexone: Current evidence. Annals of the New York Academy of Sciences 2011, 1216:144-166. 10.1111/j.1749-6632.2010.05900.x.
11. Gonzalez A., Barinas J., O'Cleirigh C. Substance use: Impact on adherence and HIV medical treatment. Current HIV/AIDS Reports 2011, 8:223-234. 10.1007/s11904-011-0093-5.
12. Harris A.H., Oliva E., Bowe T., Humphreys K.N., Kivlahan D.R., Trafton J.A. Pharmacotherapy of alcohol use disorders by the Veterans Health Administration: Patterns of receipt and persistence. Psychiatric Services 2012, 63:679-685. 10.1176/appi.ps.201000553.
13. Higgins J., Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] Retrieved from Available from. http://www.cochrane-handbook.org.
14. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002, 21:1539-1558. 10.1002/sim.1186.
15. Howard A.A., Arnsten J.H., Gourevitch M.N. Effect of alcohol consumption on diabetes mellitus: A systematic review. Annals of Internal Medicine 2004, 140:211-219.
16. Institute of Medicine Initial national priorities for comparative effectiveness research 2009, The National Academies Press, Washington, DC.
17. Knudsen H.K., Abraham A.J., Oser C.B. Barriers to the implementation of medication-assisted treatment for substance use disorders: The importance of funding policies and medical infrastructure. Evaluation and Program Planning 2011, 34:375-381. 10.1016/j.evalprogplan.2011.02.004.
18. Knudsen H.K., Abraham A.J., Roman P.M. Adoption and implementation of medications in addiction treatment programs. Journal of Addiction Medicine 2011, 5:21-27. 10.1097/ADM.0b013e3181d41ddb.
19. Knudsen H.K., Roman P.M. Financial factors and the implementation of medications for treating opioid use disorders. Journal of Addiction Medicine 2012, 6:280-286. 10.1097/ADM.0b013e318262a97a.
20. Kranzler H.R., Stephenson J.J., Montejano L., Wang S., Gastfriend D.R. Persistence with oral naltrexone for alcohol treatment: Implications for health-care utilization. Addiction 2008, 103:1801-1808. 10.1111/j.1360-0443.2008.02345.x.
21. Lee J.D., Grossman E., DiRocco D., Truncali A., Hanley K., Stevens D., et al. Extended-release naltrexone for treatment of alcohol dependence in primary care. Journal of Substance Abuse Treatment 2010, 39:14-21. 10.1016/j.jsat.2010.03.005.
22. Lindsey M., Patterson W., Ray K., Roohan P. Statistical brief #3: Potentially preventable hospital readmissions among Medicaid recipients with mental health and/or substance abuse health conditions compared with all others 2007, New York State Department of Health, Division of Quality and Evaluation, Office of Health Insurance Programs, Albany, NY.
23. Mark T.L., Montejano L.B., Kranzler H.R., Chalk M., Gastfriend D.R. Comparison of healthcare utilization among patients treated with alcoholism medications. The American Journal of Managed Care 2010, 16:879-888.
24. Mattick R.P., Breen C., Kimber J., Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane database of systematic reviews (Online) 2009, CD002209. 10.1002/14651858.CD002209.pub2.
25. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews 2008, CD002207. 10.1002/14651858.CD002207.pub3.
26. McGlynn E.A., Asch S.M., Adams J., Keesey J., Hicks J., DeCristofaro A., et al. The quality of health care delivered to adults in the United States. New England Journal of Medicine 2003, 348:2635-2645. 10.1056/NEJMsa022615.
27. Mertens J.R., Lu Y.W., Parthasarathy S., Moore C., Weisner C.M. Medical and psychiatric conditions of alcohol and drug treatment patients in an HMO: Comparison with matched controls. Archives of Internal Medicine 2003, 163:2511-2517. 10.1001/archinte.163.20.2511.
28. National Institute on Alcohol Abuse and Alcoholism Helping patients who drink too much: A clinician's guide (NIH Publication No. 07-3769 (pp. 1-34 p) 2007, (Rockville, MD. Retrieved from http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_guide.htm).
29. National Institute on Drug Abuse Principles of drug addiction treatment: A research-based guide 2009, National Institute on Drug Abuse, Bethesda, MD.
30. National Quality Forum. National voluntary consensus standards for the treatment of substance use conditions: Evidence-based treatment practices 2007, National Quality Forum, Washington, DC.
31. Parthasarathy S., Weisner C., Hu T.W., Moore C. Association of outpatient alcohol and drug treatment with health care utilization and cost: Revisiting the offset hypothesis. Journal of Studies on Alcohol 2001, 62:89-97.
32. Pettinati H.M., O'Brien C.P., Rabinowitz A.R., Wortman S.P., Oslin D.W., Kampman K.M., et al. The status of naltrexone in the treatment of alcohol dependence: Specific effects on heavy drinking. Journal of Clinical Psychopharmacology 2006, 26:610-625. 10.1097/01.jcp.0000245566.52401.20.
33. Rösner S., Hackl-Herrwerth A., Leucht S., Vecchi S., Srisurapanont M., Soyka M. Opioid antagonists for alcohol dependence. Cochrane Database of Systematic Reviews 2010, 1-258. (Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001867.pub3/abstract). 10.1002/14651858.CD001867.pub3.
34. Schneeweiss S., Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. Journal of Clinical Epidemiology 2005, 58:323-337. 10.1016/j.jclinepi.2004.10.012.
35. Sterne J.A., Sutton A.J., Ioannidis J.P., Terrin N., Jones D.R., Lau J., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ 2011, 343:302-307. 10.1136/bmj.d4002.
36. Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings (2012) 2012, (Rockville, MD. Retrieved from http://www.samhsa.gov/data/NSDUH/2k11Results/NSDUHresults2011.htm#2.16).
37. Sullivan L.E., Tetrault J.M., Braithwaite R.S., Turner B.J., Fiellin D.A. A meta-analysis of the efficacy of nonphysician brief interventions for unhealthy alcohol use: Implications for the patient-centered medical home. The American Journal on Addictions 2011, 20:343-356. 10.1111/j.1521-0391.2011.00143.x.
38. Weisner C., Mertens J., Parthasarathy S., Moore C., Lu Y. Integrating primary medical care with addiction treatment: A randomized controlled trial. JAMA 2001, 286:1715-1723.
39. Weiss R.D. Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction 2004, 99:1382-1392. 10.1111/j.1360-0443.2004.00884.x.
40. Wells, G. A., Shea, B., O'Connell, D. J., Peterson, J., Welch, V., Losos, M., & Tugwell, P. (undated). The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, from (accessed 9/27/12). http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.